Worcester, MA, July 11, 2006 " Advanced Cell Technology's (OTCBB:ACTC) Robert Lanza, M.D., Vice President of Research & Scientific Development, and his colleagues continue to receive favorable reviews for Essentials of Stem Cell Biology, the recently-released landmark volume on embryonic and adult stem cell research and its real-world applications. Dr. Lanza served as Editor-in-Chief, and co-edited the volume with several other leading experts in the area of stem cell research and regenerative medicine.
Highly praised in Nature Cell Biology, the book received critical accolades from the prestigious New England Journal of Medicine in their June 29, 2006 issue when, G�östa Gahrton, M.D., Ph.D., of the Karolinska Institute, Stockholm, Sweden, wrote: "Essentials of Stem Cell Biology belongs on the shelf of every researcher, clinician, and student who is interested in new developments in stem-cell research and the related treatment options that are being developed.”
Additionally, in a five star, 100 out of 100-point review in Doody's Book Review, the premiere book review service for more than a million healthcare professionals, Bruce A. Fenderson, Ph.D., of Thomas Jefferson University wrote: "This beautiful hardcover book provides a concise and complete introduction to the theory and practice of stem cell research… This is the best book I've reviewed on stem cell biology. Comprehensive, yet concise… This is the one book to have for anyone interested in the promise of stem cell research… it will provide an excellent resource for years to come.”
Essentials of Stem Cell Biology is an abridged version of the bestselling reference, Handbook of Stem Cells, a two-volume set. The new work incorporates all the essential subject matter of the original two-volume edition into a single volume. The material in the first set has been reworked in a more-accessible format suitable for both students and general readers interested in the latest advances in stem cells, and includes numerous full-color presentations. The new format is designed to promote better understanding of the scientific and ethical issues involved with adult and embryonic stem cell research and associated real-life applications.
Essentials of Stem Cell Biology was co-edited by thought leaders John Gearhart, Johns Hopkins University School of Medicine, Baltimore, Maryland; Brigid Hogan, Duke University Medical Center, Durham, North Carolina; Douglas Melton, Howard Hughes Medical Institute, Harvard University, Cambridge, Massachusetts; Roger Pedersen, Department of Surgery, University of Cambridge and Addenbrooke's Hospital, Cambridge, U.K.; James Thomson, Wisconsin Regional Primate Research Center, University of Wisconsin, Madison, Wisconsin; E. Donnall Thomas, Director Emeritus, Fred Hutchinson Cancer Research Center, Seattle, Washington; and Michael West, Chairman, President and Chief Scientific Officer, Advanced Cell Technology.
"At a time when harnessing the promise of stem cell therapies and bringing them to the bedside looks increasingly viable, here at ACT and at other companies and research institutions, Dr. Lanza's treatise has emerged as one that an increasing number of scientists and non-scientists alike are relying upon as an indispensable guide to understanding stem cell biology,” said William Caldwell, CEO of Advanced Cell Technology.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit "http://www.advancedcell.com.":http://www.advancedcell.com.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended March 31, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Investor Relations: "James Carbonara":mailto:email@example.com
Media Relations: Bill Douglass/Judy Katz
The Investor Relations Group